These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 18511442

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
    Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM.
    Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
    [Abstract] [Full Text] [Related]

  • 3. Oxidative stress and advanced glycation in diabetic nephropathy.
    Coughlan MT, Mibus AL, Forbes JM.
    Ann N Y Acad Sci; 2008 Apr; 1126():190-3. PubMed ID: 18448815
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
    Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP, ACTION I Investigator Group.
    Am J Nephrol; 2004 Apr; 24(1):32-40. PubMed ID: 14685005
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effects of a novel inhibitor of advanced glycation.
    Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME.
    Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
    [Abstract] [Full Text] [Related]

  • 6. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
    McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert RE.
    Kidney Int; 2007 Aug; 72(4):481-8. PubMed ID: 17554258
    [Abstract] [Full Text] [Related]

  • 7. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor.
    Koike N, Takamura T, Kaneko S.
    Life Sci; 2007 Apr 10; 80(18):1721-8. PubMed ID: 17346751
    [Abstract] [Full Text] [Related]

  • 8. XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.
    Li H, Zheng X, Wang H, Zhang Y, Xin H, Chen X.
    Eur J Pharmacol; 2010 Feb 10; 627(1-3):340-7. PubMed ID: 19895808
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H, Munusamy S.
    Protein Pept Lett; 2017 Feb 10; 24(1):71-77. PubMed ID: 27894247
    [Abstract] [Full Text] [Related]

  • 11. Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats.
    Xu M, Dai DZ, Dai Y.
    Am J Nephrol; 2009 Feb 10; 29(3):252-6. PubMed ID: 18802327
    [Abstract] [Full Text] [Related]

  • 12. Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats.
    Ito D, Cao P, Kakihana T, Sato E, Suda C, Muroya Y, Ogawa Y, Hu G, Ishii T, Ito O, Kohzuki M, Kiyomoto H.
    PLoS One; 2015 Feb 10; 10(9):e0138037. PubMed ID: 26379244
    [Abstract] [Full Text] [Related]

  • 13. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
    Miyata T, Yamamoto M, Izuhara Y.
    Ann N Y Acad Sci; 2005 Jun 10; 1043():740-9. PubMed ID: 16037301
    [Abstract] [Full Text] [Related]

  • 14. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
    Nam SM, Lee MY, Koh JH, Park JH, Shin JY, Shin YG, Koh SB, Lee EY, Chung CH.
    Diabetes Res Clin Pract; 2009 Feb 10; 83(2):176-82. PubMed ID: 19111363
    [Abstract] [Full Text] [Related]

  • 15. Effects of NADPH oxidase inhibitor in diabetic nephropathy.
    Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS.
    Kidney Int; 2005 May 10; 67(5):1890-8. PubMed ID: 15840036
    [Abstract] [Full Text] [Related]

  • 16. Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.
    Jeyabal PV, Kumar R, Gangula PR, Micci MA, Pasricha PJ.
    Neurogastroenterol Motil; 2008 Mar 10; 20(3):253-61. PubMed ID: 17971026
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
    Coughlan MT, Cooper ME, Forbes JM.
    Ann N Y Acad Sci; 2005 Jun 10; 1043():750-8. PubMed ID: 16037302
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.